
Pardes Biosciences Investor Relations Material
Latest events

Q1 2023
5 May, 2023

Q4 2022
14 Mar, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Pardes Biosciences Inc
Access all reports
Pardes Biosciences Inc. is a biopharmaceutical company that was focused on the discovery, development, and commercialization of novel oral antiviral therapeutics. The company targeted life-threatening diseases, including its efforts against COVID-19. Pardes Biosciences operated as a clinical-stage company, which indicates its products were in the clinical trial phase and not yet available on the market. As of August 31, 2023, Pardes Biosciences was acquired by MediPacific, Inc., and it became a wholly owned subsidiary of MediPacific. Following the acquisition, the shares of Pardes Biosciences ceased trading and were delisted from the Nasdaq stock exchange.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
PRDS
Country
🇺🇸 United States